{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:14:27Z","timestamp":1760548467004},"reference-count":56,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2007,8,31]]},"DOI":"10.2217\/14796694.3.4.381","type":"journal-article","created":{"date-parts":[[2007,7,30]],"date-time":"2007-07-30T10:25:46Z","timestamp":1185791146000},"page":"381-392","source":"Crossref","is-referenced-by-count":25,"title":["Trabectedin (Et-743): Evaluation of Its Use In Advanced Soft-Tissue Sarcoma"],"prefix":"10.1080","volume":"3","author":[{"given":"Patrick","family":"Sch\u00f6ffski","sequence":"first","affiliation":[{"name":"Leuven Cancer Institute, Department of General Medical Oncology, University Hospital Gasthuisberg, Catholic University Leuven, Herestraat 49, 3000Leuven, Belgium."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Wolter","sequence":"additional","affiliation":[{"name":"Leuven Cancer Institute, Department of General Medical Oncology, University Hospital Gasthuisberg, Catholic University Leuven, Herestraat 49, 3000Leuven, Belgium."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Clement","sequence":"additional","affiliation":[{"name":"Leuven Cancer Institute, Department of General Medical Oncology, University Hospital Gasthuisberg, Catholic University Leuven, Herestraat 49, 3000Leuven, Belgium."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raf","family":"Sciot","sequence":"additional","affiliation":[{"name":"Leuven Cancer Institute, Department of Pathology, University Hospital Gasthuisberg, Catholic University Leuven, Herestraat 49, 3000\u00a0Leuven, Belgium."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivo","family":"De Wever","sequence":"additional","affiliation":[{"name":"Leuven Cancer Institute, Department of Surgical Oncology, University Hospital Gasthuisberg, Catholic University Leuven, Herestraat 49, 3000\u00a0Leuven, Belgium."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Wozniak","sequence":"additional","affiliation":[{"name":"Leuven Cancer Institute, Department of General Medical Oncology, University Hospital Gasthuisberg, Catholic University Leuven, Herestraat 49, 3000Leuven, Belgium."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiana","family":"Stefan","sequence":"additional","affiliation":[{"name":"Leuven Cancer Institute, Department of General Medical Oncology, University Hospital Gasthuisberg, Catholic University Leuven, Herestraat 49, 3000Leuven, Belgium."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herlinde","family":"Dumez","sequence":"additional","affiliation":[{"name":"Leuven Cancer Institute, Department of General Medical Oncology, University Hospital Gasthuisberg, Catholic University Leuven, Herestraat 49, 3000Leuven, Belgium."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2007,7,30]]},"reference":[{"key":"e_1_3_2_3_1_1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.54.1.8"},{"key":"e_1_3_2_3_2_1","first-page":"1738","volume-title":"Cancer: Principles and Practice of Oncology","author":"Brennan MF","year":"1997","unstructured":"Brennan MF , CasperES, HarrisonL: Soft-tissue sarcoma. In: Cancer: Principles and Practice of Oncology. De VitaVT, Hellman\u00a0S, RosenbergSA(Eds) . Lippincott-Raven Publisher, PA, USA, 1738\u20131788 (1997)."},{"key":"e_1_3_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(87)90089-7"},{"key":"e_1_3_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.7.1537"},{"key":"e_1_3_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971001)80:7<1221::AID-CNCR4>3.0.CO;2-N"},{"key":"e_1_3_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00050-8"},{"key":"e_1_3_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.14.2676"},{"key":"e_1_3_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.735"},{"key":"e_1_3_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199806000-00025"},{"key":"e_1_3_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2378"},{"key":"e_1_3_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262080-00005"},{"key":"e_1_3_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565020-00002"},{"key":"e_1_3_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21867"},{"key":"e_1_3_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi960306b"},{"key":"e_1_3_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm990241l"},{"key":"e_1_3_2_3_16_1","first-page":"2908","article-title":"Sensitivity of soft-tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent","volume":"7","author":"Li WW","year":"2001","unstructured":"Li WW , TakahashiN, JhanwarSet al.: Sensitivity of soft-tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin. Cancer Res.7, 2908\u20132911 (2001).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_3_17_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008364727071"},{"key":"e_1_3_2_3_18_1","first-page":"1977","article-title":"Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts","volume":"4","author":"Valoti G","year":"1998","unstructured":"Valoti G , NicolettiMI, PellegrinoAet al.: Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin. Cancer Res.4, 1977\u20131983 (1998).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_3_19_1","volume-title":"Programs and Abstracts of the AACR-NCI EORTC International Conference","author":"Forouzeh B","year":"2001","unstructured":"Forouzeh B , HildagoM, DenisLet al.: Phase\u00a0I and pharmacokinetic study of the marine-derived DNA minor groove binder ET-743 on a weekly \u00d7\u00a03 every-4-week schedule in patients with advanced solid malignancies. Programs and Abstracts of the AACR-NCI EORTC International Conference. Miami Beach, FL, USA, 29 October\u20132 November (2001) (Abstract 373)."},{"key":"e_1_3_2_3_20_1","first-page":"231","article-title":"Phase\u00a0I and pharmacokinetic study of ecteinascidin 743 administered as a 72-h continuous intravenous infusion in patients with solid malignancies","volume":"7","author":"Ryan DP","year":"2001","unstructured":"Ryan DP , SupkoJG, EderJPet al.: Phase\u00a0I and pharmacokinetic study of ecteinascidin 743 administered as a 72-h continuous intravenous infusion in patients with solid malignancies. Clin. Cancer Res.7, 231\u2013242 (2001).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.5.1256"},{"key":"e_1_3_2_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(03)00458-1"},{"key":"e_1_3_2_3_23_1","first-page":"4725","article-title":"Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin-743 in a Phase I dose-finding study","volume":"6","author":"van Kesteren C","year":"2000","unstructured":"van Kesteren C , CvitkovicE, TaammaAet al.: Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin-743 in a Phase I dose-finding study. Clin. Cancer Res.6, 4725\u20134732 (2000).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200204000-00007"},{"key":"e_1_3_2_3_25_1","first-page":"75","article-title":"A Phase\u00a0I and pharmacokinetic study of ecteinascidin-743 on a daily \u00d7\u00a05 schedule in patients with solid malignancies","volume":"8","author":"Villalona-Calero MA","year":"2002","unstructured":"Villalona-Calero MA , EckhardtSG, WeissGet al.: A Phase\u00a0I and pharmacokinetic study of ecteinascidin-743 on a daily \u00d7\u00a05 schedule in patients with solid malignancies. Clin. Cancer Res.8, 75\u201385 (2002).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_3_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.672.11.2"},{"key":"e_1_3_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-002-0498-3"},{"key":"e_1_3_2_3_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.cad.0000180121.16407.38"},{"key":"e_1_3_2_3_29_1","first-page":"2952","article-title":"Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin-743 does not predict gender-dependent toxicity in humans","volume":"8","author":"Reid JM","year":"2002","unstructured":"Reid JM , KuffelMJ, RubenSLet al.: Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin-743 does not predict gender-dependent toxicity in humans. Clin. Cancer Res.8, 2952\u20132962 (2002).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_3_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-005-2902-4"},{"key":"e_1_3_2_3_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.150"},{"key":"e_1_3_2_3_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.02.098"},{"key":"e_1_3_2_3_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.180"},{"key":"e_1_3_2_3_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.210"},{"key":"e_1_3_2_3_35_1","volume-title":"Program and Abstracts of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","author":"Le Cesne A","year":"2003","unstructured":"Le Cesne A , DemetriG, JeanLet al: Impact of Yondelis in the natural history of patients with pretreated advanced soft-tissue sarcomas: Long-term follow-up results. Program and Abstracts of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Boston, MA, USA, 17\u201321 November (2003) (Abstract 31)."},{"key":"e_1_3_2_3_36_1","volume-title":"Program and Abstracts of the 43rd ASCO Annual Meeting","author":"Morgan JA","year":"2007","unstructured":"Morgan JA , Le CesneA, ChawlaSPet al.: Randomized Phase\u00a0II study of trabectedin in patients with liposarcoma and leiomyosarcoma after failure of prior anthracycline and ifosfamide. Program and Abstracts of the 43rd ASCO Annual MeetingChicago, IL, USA, 1\u20135 June (2007) (Abstract 10.60)."},{"issue":"14","key":"e_1_3_2_3_37_1","article-title":"Randomized Phase\u00a0II study of trabectedin (ET-743) given by two different dosing schedules in patients with leiomyosarcomas or liposarcomas refractory to conventional doxorubicin and ifosfamide chemotherapy. Program and Abstracts of the 40th ASCO Annual Meeting. New Orleans, LA, USA, 5\u20138 June (2004)","volume":"22","author":"Samuels BL","year":"2004","unstructured":"Samuels BL , RushingD, ChawlaSPet al: Randomized Phase\u00a0II study of trabectedin (ET-743) given by two different dosing schedules in patients with leiomyosarcomas or liposarcomas refractory to conventional doxorubicin and ifosfamide chemotherapy. Program and Abstracts of the 40th ASCO Annual Meeting. New Orleans, LA, USA, 5\u20138 June (2004). J.\u00a0Clin. Oncol.22(14S) (2004) (Abstract 9000).","journal-title":"J.\u00a0Clin. Oncol."},{"key":"e_1_3_2_3_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.028"},{"key":"e_1_3_2_3_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.7.1269"},{"key":"e_1_3_2_3_40_1","first-page":"5902","article-title":"Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug Yondelis\u2122 (ET-743) in the rat","volume":"63","author":"Donald S","year":"2003","unstructured":"Donald S , VerschoyleRD, GreavesPet al.: Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug Yondelis\u2122 (ET-743) in the rat. Cancer Res.63, 5902\u20135908 (2003).","journal-title":"Cancer Res."},{"key":"e_1_3_2_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.02.010"},{"key":"e_1_3_2_3_42_1","volume-title":"43rd ASCO Annual Meeting","author":"Sch\u00f6ffski P","year":"2007","unstructured":"Sch\u00f6ffski P : DNA repair functionality as a molecular signature for sensitivity\/resistance in sarcoma patients treated with trabectedin. Presented at: 43rd ASCO Annual Meeting. Los Angeles, CA, USA, April 14\u201318 (2007)."},{"issue":"18","key":"e_1_3_2_3_43_1","article-title":"Patterns of tumor response to trabectedin in myxoid liposarcomas. Program and Abstracts of the 42nd ASCO Annual Meeting. Atlanta, GA, USA, 2\u20136 June (2006)","volume":"24","author":"Grosso F","year":"2006","unstructured":"Grosso F , DemetriG, BlayJYet al.: Patterns of tumor response to trabectedin in myxoid liposarcomas. Program and Abstracts of the 42nd ASCO Annual Meeting. Atlanta, GA, USA, 2\u20136 June (2006). J.\u00a0Clin. Oncol.24(18S) (2006) (Abstract 9511).","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"18","key":"e_1_3_2_3_44_1","article-title":"Phase\u00a0II open label randomized study of trabectedin given as two different dosing schedules in women with platinum-sensitive, recurrent ovarian carcinoma: Preliminary results. Program and Abstracts of the 42nd ASCO Annual Meeting. Atlanta, GA, USA, 2\u20136 June (2006)","volume":"24","author":"Del Campo J","year":"2006","unstructured":"Del Campo J , RoszakA, CiuleanuTet al.: Phase\u00a0II open label randomized study of trabectedin given as two different dosing schedules in women with platinum-sensitive, recurrent ovarian carcinoma: Preliminary results. Program and Abstracts of the 42nd ASCO Annual Meeting. Atlanta, GA, USA, 2\u20136 June (2006). J.\u00a0Clin. Oncol.24(18S) (2006) (Abstract 5031).","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"16","key":"e_1_3_2_3_45_1","article-title":"Final results of a Phase\u00a0II study of weekly trabectedin in second\/third line ovarian cancer. Program and Abstracts of the 41st ASCO Annual Meeting. Orlando, FL, USA, 13\u201317 May (2005)","volume":"23","author":"McMeekin DS","year":"2005","unstructured":"McMeekin DS , KrasnerC, ChanSet al.: Final results of a Phase\u00a0II study of weekly trabectedin in second\/third line ovarian cancer. Program and Abstracts of the 41st ASCO Annual Meeting. Orlando, FL, USA, 13\u201317 May (2005). J.\u00a0Clin. Oncol.23(16S) (2005) (Abstract 5011).","journal-title":"J.\u00a0Clin. Oncol."},{"key":"e_1_3_2_3_46_1","volume-title":"43rd ASCO Annual Meeting.","author":"McMeekin S","year":"2007","unstructured":"McMeekin S , del CampoJM, ColomboNet al.: Trabectedin in relapsed advanced ovarian cancer: a pooled analysis of three Phase\u00a0II studies. Presented at: 43rd ASCO Annual Meeting.Chicago, IL, USA, 1\u20135 June (2007) (Abstract 5579)."},{"key":"e_1_3_2_3_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.032"},{"issue":"16","key":"e_1_3_2_3_48_1","article-title":"Trabectedin in third line breast cancer: a\u00a0multicenter, randomized, Phase\u00a0II study comparing two administration regimens. Program and Abstracts of the 41st ASCO Annual Meeting. Orlando, FL, USA, 13\u201317 May (2005)","volume":"23","author":"Gurtler JS","year":"2005","unstructured":"Gurtler JS , GoldsteinL, DelpreteSet al.: Trabectedin in third line breast cancer: a\u00a0multicenter, randomized, Phase\u00a0II study comparing two administration regimens. Program and Abstracts of the 41st ASCO Annual Meeting. Orlando, FL, USA, 13\u201317 May (2005). J.\u00a0Clin. Oncol.23(16S) (2005) (Abstract 625).","journal-title":"J.\u00a0Clin. Oncol."},{"key":"e_1_3_2_3_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603142"},{"issue":"16","key":"e_1_3_2_3_50_1","article-title":"Phase\u00a0II study of three h, weekly infusion of trabectedin in men with metastatic, androgen-independent prostate carcinoma. Program and Abstracts of the 41st ASCO Annual Meeting. Orlando, FL, USA, 13\u201317 May (2005)","volume":"23","author":"Michaelson T","year":"2005","unstructured":"Michaelson T , GilliganW, KantoffMEet al: Phase\u00a0II study of three h, weekly infusion of trabectedin in men with metastatic, androgen-independent prostate carcinoma. Program and Abstracts of the 41st ASCO Annual Meeting. Orlando, FL, USA, 13\u201317 May (2005). J.\u00a0Clin. Oncol.23(16S) (2005) (Abstract 4517).","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"16","key":"e_1_3_2_3_51_1","article-title":"Final results of a combination study between trabectedin and pegylated liposomal doxorubicin in patients with advanced malignancies. Program and Abstracts of the 41st ASCO Annual Meeting. Orlando, FL, USA, 13\u201317 May (2005)","volume":"23","author":"Cohen RB","year":"2005","unstructured":"Cohen RB , SchilderRJ, ChengJet al.: Final results of a combination study between trabectedin and pegylated liposomal doxorubicin in patients with advanced malignancies. Program and Abstracts of the 41st ASCO Annual Meeting. Orlando, FL, USA, 13\u201317 May (2005). J.\u00a0Clin. Oncol.23(16S) (2005) (Abstract 3074).","journal-title":"J.\u00a0Clin. Oncol."},{"key":"e_1_3_2_3_52_1","volume-title":"Programs and Abstracts of the AACR-NCI EORTC International Conference","author":"Gianni L","year":"2003","unstructured":"Gianni L , GrasselliG, De BraudFet al.: Definition of the least toxic sequence and optimal therapeutic dose of Yondelis\u2122 in combination with doxorubicin in patients with untreated metastatic soft-tissue sarcomas and advanced pre-treated anthracycline-naive breast cancer patients. Programs and Abstracts of the AACR-NCI EORTC International Conference. Boston, MA, USA, 26\u201330 October (2003) (Abstract A49)."},{"issue":"18","key":"e_1_3_2_3_53_1","article-title":"Phase\u00a0I combination study of trabectedin and capecitabine in patients with advanced malignancies. Program and Abstracts of the 42nd ASCO Annual Meeting. Atlanta, GA, USA, 2\u20136 June (2006)","volume":"24","author":"Gore L","year":"2006","unstructured":"Gore L , RiveraE, LavalleeKet al.: Phase\u00a0I combination study of trabectedin and capecitabine in patients with advanced malignancies. Program and Abstracts of the 42nd ASCO Annual Meeting. Atlanta, GA, USA, 2\u20136 June (2006). J.\u00a0Clin. Oncol.24(18S) (2006) (Abstract 2079).","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"18","key":"e_1_3_2_3_54_1","article-title":"Phase\u00a0I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2\u00a0weeks in patients with advanced solid tumors. Program and Abstracts of the 42nd ASCO Annual Meeting. Atlanta, GA, USA, 2\u20136 June (2006)","volume":"24","author":"Papadopoulos KP","year":"2006","unstructured":"Papadopoulos KP , ChuQ, PatnaikAet al.: Phase\u00a0I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2\u00a0weeks in patients with advanced solid tumors. Program and Abstracts of the 42nd ASCO Annual Meeting. Atlanta, GA, USA, 2\u20136 June (2006). J.\u00a0Clin. Oncol.24(18S) (2006) (Abstract 2029).","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"18","key":"e_1_3_2_3_55_1","article-title":"Phase\u00a0I study of trabectedin in combination with docetaxel in patients with advanced malignancies. Program and Abstracts of the 42nd ASCO Annual Meeting. Atlanta, GA, USA, 2\u20136 June (2006)","volume":"24","author":"von Mehren M","year":"2006","unstructured":"von Mehren M , BuckD, TemmerEet al.: Phase\u00a0I study of trabectedin in combination with docetaxel in patients with advanced malignancies. Program and Abstracts of the 42nd ASCO Annual Meeting. Atlanta, GA, USA, 2\u20136 June (2006). J.\u00a0Clin. Oncol.24(18S) (2006) (Abstract 2068).","journal-title":"J.\u00a0Clin. Oncol."},{"key":"e_1_3_2_3_56_1","volume-title":"43rd ASCO Annual Meeting","author":"Blay JY","year":"2007","unstructured":"Blay JY , von MehrenM, SamuelsBPet al.: Combination of trabectedin (T) and doxorubicin (D) for the treatment of patients with soft-tissue sarcoma (STS): Safety and efficacy analysis. Presented at: 43rd ASCO Annual Meeting. Chicago, IL, USA, 1\u20135 June) (2007) (Abstract 10.78)."}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/14796694.3.4.381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:44:43Z","timestamp":1719125083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/14796694.3.4.381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,30]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,8,31]]}},"alternative-id":["10.2217\/14796694.3.4.381"],"URL":"https:\/\/doi.org\/10.2217\/14796694.3.4.381","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,30]]}}}